Merck Canada said it has successfully completed negotiations on its PAH therapy Winrevair with the pan‑Canadian Pharmaceutical Alliance.

Merck plans a Phase 3 trial of Winrevair after a Phase 2 study testing it in CpcPH due to HFpEF hit its main goal.

Columnist Anna Jeter writes that, despite any setbacks, people with pulmonary hypertension should continue to take charge of their care.

A routine surgery ended up causing life-threatening complications and a health crisis for columnist Mike Naple, who is glad ...

Low oxygen levels, or hypoxia, in early life impaired lung blood vessel growth, leading to severe pulmonary hypertension in a ...

Calcimedica's CM5480 was shown to improve blood flow and heart health measurements in a rat model of PAH, a new study reports ...

Being a PH advocate is meaningful work, says columnist Jolie Lizana, who understands how much an encouraging word means to ...

Cereno Scientific is seeking FDA clearance to launch a global clinical trial testing its CS1 therapy for pulmonary arterial ...

The first clinical site is open for the global SERENATA trial testing inhaled seralutinib for pulmonary hypertension linked to lung scarring.

Data showed that the expression (activity) of the ABCA3 gene was lower in IPAH patients, while that of the SMAD9 gene was ...

Columnist Colleen Steele interviews a family caregiver who speaks in memory of her late father, who thrived despite a PH ...

Treprostinil may be safe and effective at managing pulmonary hypertension in children who underwent Fontan surgery, according to a study.